Videos

The clinical research director at the UCSF Multiple Sclerosis Center discussed potential future assessments of inebilizumab (Uplizna; Viela Bio) and the agents still in development for NMOSD.

The head of Neurology Medical at Lundbeck Seattle Biopharmaceuticals offers perspective on the findings and what impact eptinezumab may have on migraine care.

The assistant professor of neurosurgery at Yale School of Medicine spoke to the observations she and colleagues made to better understand the process of cell death and corpse removal in the brain.

Neurology News Network for the week ending July 11, 2020.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on the feasibility of genotyping, phasing, and targeting of SNPs in Huntington disease.

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

The associate professor of neurology at Vanderbilt University Medical Center spoke to the findings of a recent study in Huntington disease that assessed the feasibility of selectively knocking down mutant protein expression.

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

The associate professor of neurology at Vanderbilt University Medical Center offered his perspective on his and colleagues’ study of single nucleotide polymorphisms in Huntington disease.

Neurology News Network for the week ending July 4, 2020.

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.

Neurology News Network for the week ending June 27, 2020.

The neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis and co-principal investigator of the CAVS-MS study details the specific reasons for examining central vein sign as a biomarker.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the efficacy of inebilizumab (Uplizna; Viela Bio) and biomarker data observed in the N-Momentum trial in NMOSD.

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.

The clinical research director at the UCSF Multiple Sclerosis Center shared his perspective on the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.

The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.

Neurology News Network for the week ending June 20, 2020.

The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the anticipated impact of the recent FDA approval of inebilizumab (Uplizna; Viela Bio) for NMOSD.

The neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis and co-principal investigator of the CAVS-MS study discusses the reasons for the high rates of misdiagnosed MS.